ArriVent BioPharma, Inc. (AVBP): EPS (Diluted)
-$4.32
Year ended 2025-12-31
| Period ended | EPS (Diluted) | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$4.32 | n/m | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | -$2.56 | n/m | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | -$32.38 | n/a | 2025-03-03, From 2023-01-01 |
EPS (Diluted) at similar companies
| Company | Year ended | EPS (Diluted) | Change YoY |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | 2025-12-31 | -$4.32 | n/m |
| Amylyx Pharmaceuticals, Inc. (AMLX) | 2025-12-31 | -$1.53 | n/m |
| Rocket Pharmaceuticals, Inc. (RCKT) | 2025-12-31 | -$2.01 | n/m |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $2.30 | n/m |
| Liquidia Corp (LQDA) | 2025-12-31 | -$0.80 | n/m |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | -$1.74 | n/m |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | -$4.53 | n/m |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | -$16.06 | n/m |
| Sionna Therapeutics, Inc. (SION) | 2025-12-31 | -$1.88 | n/m |
Compare AVBP, AMLX, RCKT, KROS side by side · Screen every company in Pharmaceutical Preparations ↗